New Alzheimer's drugs could spell 'beginning of the end' for disease

A promising new Alzheimer's drug could help spell "the beginning of the end" for the neurodegenerative disease. US pharmaceutical giant Eli Lilly will announce the full clinical trial results for its Alzheimer's drug donanemab at a conference in Amsterdam today. Estimates suggest the drugs could help 720,000 people, according to the Alzheimer's Society and Alzheimer's Research UK, including 286,000 with mild Alzheimer's and 435,000 with mild cognitive impairment, which is a precursor to the disease. Pic: APIs UK ready for new Alzheimer's drugs? You can use the buttons below to amend your preferences to enable Spreaker cookies or to allow those cookies just once.